Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...

Scalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...